EP Patent

EP1564210B1 — 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors

Assigned to Japan Tobacco Inc · Expires 2009-09-16 · 17y expired

What this patent protects

4-Oxoquinoline compounds represented by the following general formula [I]: [I] wherein each symbol has the meaning as defined in the description; or pharmaceutically acceptable salts thereof and anti-HIV agents containing these compounds. Because of having an activity of inhibiti…

USPTO Abstract

4-Oxoquinoline compounds represented by the following general formula [I]: [I] wherein each symbol has the meaning as defined in the description; or pharmaceutically acceptable salts thereof and anti-HIV agents containing these compounds. Because of having an activity of inhibiting HIV integrase, the above compounds are useful as anti-HIV agents in remedies or preventives for AIDS. By using together with other anti-HIV agents such as a protease inhibitor and a reverse transcriptase inhibitor, the above compounds can be used as more efficacious anti-HIV agents. Because of having a high inhibitory activity specific to the integrase, furthermore, these compounds are usable as drugs which are safe to the human body with little side effect.

Drugs covered by this patent

Patent Metadata

Patent number
EP1564210B1
Jurisdiction
EP
Classification
Expires
2009-09-16
Drug substance claim
No
Drug product claim
No
Assignee
Japan Tobacco Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.